Business Wire

Eigenmann & Veronelli Group Successfully Completes Spin-off of Its Industrial Activities to EV Produzione

3.3.2025 14:42:00 CET | Business Wire | Press Release

Share

Eigenmann & Veronelli (EV), Italy’s leading and internationally focused distributor of specialty chemicals and food ingredients, today announces that it has successfully completed the spin-off of its manufacturing operations to EV Produzione Srl. The newly incorporated company inherits a heritage of over 110 years of experience and marks a strategic turning point for the Group.

Specializing in the manufacturing of chemical products for industry, with a consolidated turnover of over € 40 million in 2024, EV Produzione employs around 90 people dislocated in the industrial plants of San Martino di Trecate (NO) and Tradate (VA) and in the two research centers, located at the same sites. EV Produzione is now an independent unit with its own board of directors.

Covering a combined total area of 75,000 square meters, the manufacturing plants are a solid presence in the country producing mixtures, emulsions, defoamers, esters, metal soaps and other chemical specialties used in the cosmetics, rubber and plastics, surface coatings, home care and institutional & industrial cleaning industries, and numerous other applications.

The plants ensure operational versatility while maintaining the quality and innovation of the EV products brand, which are distributed in Italy and exported to over 45 countries. The significant investments outlined in the new industrial plan will secure the continuation of the winning combination of high product standards and versatility, thanks to which EV can supply the market with cutting-edge solutions that address current environmental challenges through innovation.

EV Produzione is central to this transformation, which will generate new value and foster the long-term growth of the Group.

"I am satisfied with the success of the spin-off, which is a strategic initiative that highlights our commitment to long-term value creation. In line with the vision, we will confidently guide the Group towards a more sustainable future, and I would like to take this opportunity to wish our colleagues at EV Produzione every success going forward," said Gabriele Bonomi, CEO of the Eigenmann & Veronelli Group.

"The new business plan will allow us to face the crucial challenge of sustainability with a significant focus on investments in product and process innovation, which will improve our competitiveness," commented Marco Tomei, CEO of EV Produzione. "The research centers, combined with the manufacturing plants, will enable us to assume a decisive and leading role in advanced technologies for specialty chemicals, both locally and globally."

EVGROUP

Founded in 1910, Eigenmann & Veronelli Group is an international solutions provider of specialty chemicals and food ingredients. Headquartered in Pero, Italy, EV has a direct presence in Italy, Iberia, Turkey, and the U.A.E. and a commercial reach in more than 45 countries. In 2024, EV generated a consolidated turnover of 347 million euros with more than 350 employees. With over a century of experience, EV is synonymous with effectiveness and efficiency, combining local market knowledge with chemical innovations, and offering a high-quality and diversified portfolio of specialty chemicals and ingredients as well as tailor-made application, marketing and supply chain solutions, technical and formulation support, and comprehensive regulatory know-how for a wide range of industries.

www.eigver.com

Follow us on LinkedIn

Follow us on YouTube

View source version on businesswire.com: https://www.businesswire.com/news/home/20250303516199/en/

Contacts

Press Contacts
For further enquiries, please contact:
Federica Urso
Corporate Communications Director, EV Group
Mob. (+39) 338 7295116
@: furso@eigver.it
Miriam Bolzoni
PR & Media Relations, EV Group
@: mediarelations@eigver.it

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye